SiBone (SIBN) Stock Price, News & Analysis

Company Overview

SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures. The company provides associated instruments and surgical technologies to support these procedures.

Founded in 2008 and headquartered in Santa Clara, California, SI-BONE markets its products primarily in the United States and also serves select international markets. Its solutions are used by spine and orthopedic surgeons in hospitals and other surgical settings. SI-BONE became a publicly traded company in 2018.

Key Stats

• Today's Range: $23.55 to $24.53
• 50-Day Range: $18.04 to $24.95
• 52-Week Range: $11.48 to $25.92
• Volume: 683,472 shs
• Average Volume: 654,887 shs
• Market Capitalization: $1.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Moderate Buy

SiBone Stock Analysis - MarketRank™

SiBone scored higher than 39% of companies evaluated by MarketBeat, and ranked 657th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

SiBone has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for SiBone is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

SiBone has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SiBone are expected to grow in the coming year, from ($0.34) to ($0.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SiBone is -78.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SiBone is -78.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SiBone has a P/B Ratio of 5.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.05% of the float of SiBone has been sold short.

Short Interest Ratio / Days to Cover

SiBone has a short interest ratio ("days to cover") of 8.67.

Change versus previous month

Short interest in SiBone has recently decreased by 8.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SiBone does not currently pay a dividend.

Dividend Growth

SiBone does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.41

News Sentiment

SiBone has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 39 news articles for SiBone this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for SIBN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added SiBone to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, SiBone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,034,168.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of SiBone is held by insiders.

Percentage Held by Institutions

98.11% of the stock of SiBone is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/02/2026
• Today: 11/07/2026
• UBS Global Healthcare Conference: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:SIBN
• CIK: 1459839
• Web: www.si-bone.com
• Phone: (408) 207-0700
• Fax: N/A
• Employees: 376
• Year Founded: 2008

Price Target and Rating

• Average Price Target for SiBone: $25.00
• High Price Target: $27.00
• Low Price Target: $23.00
• Potential Upside/Downside: +3.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.90 million
• Net Margins: -6.20%
• Pretax Margin: -6.85%
• Return on Equity: -7.62%
• Return on Assets: -5.63%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 9.15
• Quick Ratio: 7.55

Sales & Book Value

• Annual Sales: $200.93 million
• Price / Sales: 5.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.09 per share
• Price / Book: 5.93

Miscellaneous

• Outstanding Shares: 44,350,000
• Free Float: 43,308,000
• Market Cap: $1.08 billion
• Optionable: Optionable
• Beta: 0.64